Braftovi
Term · Oncology and biomedicine · MLC-T-ONC-001210
A drug used with cetuximab to treat certain types of colorectal cancer and with binimetinib to treat certain types of melanoma and non-small cell lung cancer. It is used in patients whose cancer has a certain mutation (change) in the BRAF gene. It is also being studied in the treatment of other types of cancer. Braftovi blocks certain proteins made by the mutated BRAF gene, which may help keep cancer cells from growing. It is a type of kinase inhibitor. Also called encorafenib.
| Identifier | MLC-T-ONC-001210 |
|---|---|
| Field | Oncology and biomedicine |
| Synonyms | encorafenib |
| References | NCI Dictionary of Cancer Terms |
Record as JSON
{
"id": "MLC-T-ONC-001210",
"term": "Braftovi",
"field": "Oncology and biomedicine",
"definition": "A drug used with cetuximab to treat certain types of colorectal cancer and with binimetinib to treat certain types of melanoma and non-small cell lung cancer. It is used in patients whose cancer has a certain mutation (change) in the BRAF gene. It is also being studied in the treatment of other types of cancer. Braftovi blocks certain proteins made by the mutated BRAF gene, which may help keep cancer cells from growing. It is a type of kinase inhibitor. Also called encorafenib.",
"synonyms": [
"encorafenib"
],
"references": [
"NCI Dictionary of Cancer Terms"
],
"url": "https://mlchart.com/terminology/oncology/braftovi/"
}
Record 3,798 of 17,717 in Oncology and biomedicine terminology (MLC-0111). Request the full dataset.